Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
VAXESS TECHNOLOGIES, INC. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active case is being processed by a distinct examiner in a distinct art unit. This suggests that the company's current patent activity is focused on a specific technical challenge within the biotech sector, rather than being distributed across multiple examiners.
The busiest examiner, ALLEY, GENEVIEVE S, is currently managing the 1 pending office action. As the examiner for the company's active matters, this individual's interpretation of the claims will be the primary factor in the prosecution. Strategy should be tailored to the specific examination style of this person. The examiner's experience in the Biotechnology & Pharmaceuticals area will likely influence the scope of the allowed claims.
The presence of the distinct art unit ensures that the company is subject to a uniform set of examination standards. This lack of departmental variety simplifies the oversight of the active office action. The current prosecution profile is characterized by its singular focus and lack of distribution across the patent office, allowing for a concentrated legal effort.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEY, GENEVIEVE S | 1 | 60.3% | +48.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17714025 | SILK FIBROIN-BASED MICRONEEDLES AND USES THEREOF | ALLEY, GENEVIEVE S | 76d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17714025 | SILK FIBROIN-BASED MICRONEEDLES AND USES THEREOF | ALLEY, GENEVIEVE S | 76d |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17714025 | SILK FIBROIN-BASED MICRONEEDLES AND USES THEREOF | ALLEY, GENEVIEVE S | 1617 | §102§103§112 | Non-Final OA | 76d | Pending | Apr 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial